非NF2突变对颅底脑膜瘤抑制性免疫检查点及肿瘤发病机制的关键影响
该研究通过Sanger测序在92例颅底脑膜瘤中检测TRAF7、KLF4、AKT1和SMO突变,并用免疫组化和Western blot比较突变型与野生型肿瘤中PD-L1、IDO和TDO2的表达差异。结果显示TRAF7突变肿瘤中PD-L1、IDO和TDO2水平显著高于野生型,AKT1突变与野生型间TDO2有显著差异,提示检查点抑制剂可能成为这些突变脑膜瘤的靶向免疫治疗策略。
要点
- TRAF7突变颅底脑膜瘤的PD-L1、IDO和TDO2表达显著高于野生型。
- AKT1突变与野生型肿瘤间TDO2表达存在显著差异。
- 检查点抑制剂可能成为这些突变脑膜瘤的靶向免疫治疗策略。
核心结论
- TRAF7突变可能通过调控抑制性免疫检查点表达抑制免疫反应,在颅底脑膜瘤中起关键作用。
- 检查点抑制剂可能成为这些突变脑膜瘤的靶向免疫治疗潜在策略。
研究设计与样本
- 研究纳入92例颅底脑膜瘤,采用Sanger测序检测TRAF7、KLF4、AKT1和SMO四个基因的突变。
- 采用免疫组化和Western blot比较突变型与野生型肿瘤中免疫检查点分子的表达差异。
主要发现
- 四种突变在颅底脑膜瘤患者中未同时检出。
- KLF4突变组中几乎一半为岩斜区脑膜瘤,KLF4和TRAF7突变肿瘤主要为分泌型脑膜瘤。
- SMO突变肿瘤钙化更高,其中一半位于脑中线。
- ROC曲线分析表明肿瘤体积可分别以高灵敏度和特异度预测KLF4和TRAF7突变状态。
- TRAF7突变肿瘤中PD-L1、IDO和TDO2水平显著高于野生型,AKT1突变与野生型间TDO2有显著差异。
关键数值与推荐
- 颅底脑膜瘤约占所有脑膜瘤的25%,其中近20%为非典型或间变性。
临床怎么用
- 对颅底脑膜瘤可考虑检测TRAF7、KLF4、AKT1和SMO突变以辅助分子分型。
- TRAF7突变肿瘤高表达PD-L1、IDO和TDO2,提示检查点抑制剂或可作为靶向免疫治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Skull base meningiomas represent approximately 25% of all meningiomas, nearly 20% of which are atypical or anaplastic. To date, effective medical treatments for meningiomas are still lacking. Genetic aberrations (TRAF7, KLF4, AKT1, and SMO) and the effects of genetic aberrations on the expression of inhibitory immune checkpoint molecules (PD-L1, IDO, and TDO2) in skull base meningiomas are still unclear. METHODS: Genetic alterations in the four genes were identified in 92 skull base meningiomas by Sanger sequencing. The expression differences in immune checkpoints between mutant and wild-type (WT) tumors were determined by immunohistochemistry (IHC) and Western blot (WB). RESULTS: The four mutations were not concurrently detected in the patients with skull base meningiomas. Among the tumors from the KLF4-mutated group, almost half were petroclival meningiomas. KLF4- and TRAF7-mutated tumors were predominantly secretory meningiomas. SMO-mutated tumors exhibited higher calcification, and half of these tumors were observed in the brain midline. Receiver operating characteristic curve analysis indicated that tumor volume can predict KLF4 and TRAF7 mutation status with high sensitivity and specificity, respectively. The IHC and WB analyses indicated that PD-L1, IDO, and TDO2 levels in tumors with TRAF7 mutations were significantly higher than those in WT tumors. Meanwhile, there was a significant difference in TDO2 between tumors with AKT1 mutations and WT tumors. Specifically, TRAF7 mutations could play a key role in skull base meningiomas by regulating the expression of inhibitory immune checkpoints and thus suppressing immune responses. CONCLUSIONS: Checkpoint inhibitors may be potential strategies for targeted immunotherapies of these mutant meningiomas.
引用
- Hao S, Huang G, Feng J, et al. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas. J Neurooncol. 2019. PMID: 31177425. doi:10.1007/s11060-019-03198-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。